What's Happening?
Atisama Therapeutics, an Australian biotechnology company, has announced advancements in the Phase 1 trial of its lead candidate, RB042, and the appointment of Dr. Bernard Coulie as Chair of the Board.
RB042, an inhaled splice-switching oligonucleotide targeting the Receptor for Advanced Glycation End-products (RAGE), is being tested for its potential to treat chronic obstructive pulmonary disease (COPD). The trial has progressed to multiple ascending dose cohorts, demonstrating safety and tolerability. Dr. Coulie, with extensive experience in pulmonary disease, joins Atisama at a critical time as the company prepares for further growth and development of its therapeutic pipeline.
Why It's Important?
The progress of RB042 in clinical trials is a significant development in the treatment of COPD, a major global health issue. With COPD being the third leading cause of death worldwide, the potential of RB042 to offer a targeted therapeutic option for non-eosinophilic patients is noteworthy. The appointment of Dr. Coulie, with his expertise in pulmonary disease and biopharma leadership, is expected to strengthen Atisama's strategic direction and governance. This development could accelerate the advancement of RB042 and other therapies in Atisama's pipeline, potentially leading to new treatment options for inflammatory diseases.
